| 0 (0%) | 07-05 20:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.51 |
1-year : | 38.54 |
| Resists | First : | 26.12 |
Second : | 33 |
| Pivot price | 23.41  |
|||
| Supports | First : | 15 |
Second : | 12.48 |
| MAs | MA(5) : | 25.69 |
MA(20) : | 22.58 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 1.3 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 48 |
D(3) : | 57.6 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 33 | Low : | 15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AMKL ] has closed above bottom band by 38.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 23.47 - 23.58 | 23.58 - 23.7 |
| Low: | 20.44 - 20.57 | 20.57 - 20.7 |
| Close: | 21.02 - 21.23 | 21.23 - 21.44 |
Tue, 30 Jun 2026
Lineage-restricted dependency on an oncofetal SNHG29 -IGF2BP1 RNA axis in acute megakaryoblastic leukemia - Nature
Mon, 08 Jun 2026
AMKL | Defiance Daily Target 2X Institutional Ownership - Quiver Quantitative
Tue, 05 May 2026
Defiance launches amkl the first daily 2x long ETF for Amkor Technology, Inc. - marketscreener.com
Tue, 05 May 2026
Defiance Launches AMKL: The First Daily 2X Long ETF for Amkor Technology, Inc. - GlobeNewswire
Sun, 29 Mar 2026
Acute Megakaryoblastic Leukemia With Myeloid Sarcoma in the Temporal Bone: A Case Report - Cureus
Thu, 28 Aug 2025
Yale Study: Potential Treatment Pathway Found for Rare and Aggressive Leukemia - Yale School of Medicine
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|